To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

This bill would cancel changes the FDA made in January 2023 to how mifepristone, a medication used to end pregnancies, can be given to patients. Before the changes, patients had to pick up the medication in person at clinics, medical offices, or hospitals. The FDA's 2023 changes removed this in-person requirement and instead allowed certified retail pharmacies to dispense the medication by mail or in stores if prescribed by certified doctors. The bill would bring back the old in-person requirement and prevent similar changes in the future.

Your Vote